Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-19
DOI
10.1038/s41467-022-29794-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- (2021) Carl M. Gay et al. CANCER CELL
- Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation
- (2021) Alvaro Quintanal-Villalonga et al. Cancer Discovery
- Lineage plasticity in cancer: a shared pathway of therapeutic resistance
- (2020) Álvaro Quintanal-Villalonga et al. Nature Reviews Clinical Oncology
- The rare YAP1 subtype of Small Cell Lung Cancer revisited in a biobank of 39 Circulating Tumour Cell Patient Derived eXplant models (CDX): A brief report
- (2020) Sarah M. Pearsall et al. Journal of Thoracic Oncology
- Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization
- (2020) Marina K. Baine et al. Journal of Thoracic Oncology
- SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
- (2020) Camille Tlemsani et al. Cell Reports
- Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
- (2020) Fang Huang et al. JOURNAL OF CLINICAL INVESTIGATION
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- (2020) Jonathan W Goldman et al. LANCET ONCOLOGY
- Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
- (2020) Corrin A. Wohlhieter et al. Cell Reports
- LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma
- (2019) Ana Galan-Cobo et al. CANCER RESEARCH
- MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
- (2019) Milind D. Chalishazar et al. CLINICAL CANCER RESEARCH
- Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
- (2019) Michael Offin et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
- (2018) Yu-Han Huang et al. GENES & DEVELOPMENT
- YAP/TAZ upstream signals and downstream responses
- (2018) Antonio Totaro et al. NATURE CELL BIOLOGY
- Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
- (2018) Benjamin J. Drapkin et al. Cancer Discovery
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- Skn-1a/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice
- (2017) Junpei Yamashita et al. PLoS One
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer
- (2016) Louise Carter et al. NATURE MEDICINE
- FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
- (2016) Ronglai Shen et al. NUCLEIC ACIDS RESEARCH
- MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells
- (2016) Fuyumi Kato et al. Oncotarget
- Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis
- (2016) Valentina E. Schneeberger et al. PLoS One
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Small cell lung cancer: Where do we go from here?
- (2014) Lauren Averett Byers et al. CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systematic evaluation of spliced alignment programs for RNA-seq data
- (2013) Pär G Engström et al. NATURE METHODS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- DELLY: structural variant discovery by integrated paired-end and split-read analysis
- (2012) T. Rausch et al. BIOINFORMATICS
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
- (2012) Tateaki Naito et al. Journal of Thoracic Oncology
- Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma
- (2012) X. Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
- (2011) Joaquim Calbo et al. CANCER CELL
- Circulating tumor cells: approaches to isolation and characterization
- (2011) Min Yu et al. JOURNAL OF CELL BIOLOGY
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro
- (2009) V. C. Daniel et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started